Treosulfan
Alkyl Sulfonates
Sold as Trecondi · TRECONDYV
- Drug class
- Alkyl Sulfonates
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 8
Overview
Treosulfan is an active pharmaceutical ingredient in the Alkyl Sulfonates group (L01AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 17, 2026 |
| CA Canada | Health Canada | 3 | November 26, 2025 |
| EU European Union | EMA | 1 | February 17, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Treosulfan is indicated for the palliative treatment of epithelial ovarian cancer.
How to take
CACanada· Health Canada
3 products
Uses
Trecondyv® (treosulfan) is indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies, in pediatric patients older than 1 year old with AML or MDS Administration of treosulfan should be supervised by a physician experienced in conditioning treatment followed by alloHSCT.
Limitations of Use Trecondyv® is not indicated for patients undergoing allo HSCT for Fanconi anemia and other DNA breakage repair disorders. 1 Pediatrics Pediatrics (> 1 year to 18 years): The use of Trecondyv® has not been fully investigated in the pediatric population.
2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use of Trecondyv® in the geriatric population is not associated with significant differences in safety or effectiveness. No dose adjustment is necessary in any subset of the elderly population.
EUEuropean Union· EMA
1 product
Uses
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
How to take
Sources & citations
- [1]MHRA (UK) · PL115870002 · revised June 2, 2023
- [2]Health Canada (DPD) · 02517361 · revised June 5, 2025
- [3]European Medicines Agency · EMEA/H/C/004751 · revised February 17, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.